A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders

Psychiatry Research

Volumn 225, Issue 1-2, 2015, Pages 14-30

  Sendt, Kyra Verena ^a   Tracy, Derek Kenneth ^a,b   Bhattacharyya, Sagnik ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b OXLEAS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Compliance; Predictors; Psychosis; Treatment

Indexed keywords

NEUROLEPTIC AGENT;

ATTITUDE TO ILLNESS; COGNITION; CONSENSUS; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DISEASE SEVERITY; DRUG FORMULATION; ENVIRONMENTAL FACTOR; EVIDENCE BASED MEDICINE; FACTORIAL ANALYSIS; HUMAN; INTROSPECTION; LONGITUDINAL STUDY; MEDICAL INFORMATION; META ANALYSIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT INFORMATION; PHARMACOLOGICAL PARAMETERS; PREDICTION; PROSPECTIVE STUDY; PSYCHOSIS; RETROSPECTIVE STUDY; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SOCIAL INTERACTION; SOCIAL SUPPORT; SYMPTOM; SYSTEMATIC REVIEW; TREATMENT RESPONSE; ADULT; ATTITUDE TO HEALTH; FEMALE; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; PSYCHOLOGY;

ADULT; ANTIPSYCHOTIC AGENTS; ATTITUDE TO HEALTH; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PROSPECTIVE STUDIES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84916613158     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2014.11.002     Document Type: Review

References (145)

1. Abdel-Baki A., Ouellet-Plamondon C., Malla A. Pharmacotherapy challenges in patients with first-episode psychosis. Journal of Affective Disorders 2012, 138:S3-S14.
2. Acosta F.J., Bosch E., Sarmiento G., Juanes N., Caballero-Hidalgo A., Mayans T. Evaluation of noncompliance in schizophrenia patients using electronic monitoring (MEMS®) and its relationship to sociodemographic, clinical and psychopathological variables. Schizophrenia Research 2009, 107:213-217.
3. Amador X.F., Strauss D.H., Yale S.A., Flaum M.M., Endicott J., Gorman J.M. Assessment of insight in psychosis. American Journal of Psychiatry 1993, 150:873-879.
4. Anderson K.H., Ford S., Robson D., Cassis J., Rodrigues C., Gray R. An exploratory, randomized controlled trial of adherence therapy for people with schizophrenia. International Journal of Mental Health Nursing 2010, 19:340-349.
5. Andreasen N.C. The Scale for the Assessment of Positive Symptoms (SAPS) 1984, University of Iowa, Iowa City (IA), USA.
6. Andreasen N.C. The Scale for the Assessment of Negative Symptoms (SANS) 1989, University of Iowa, Iowa City (IA), USA.
7. Arana G.W. An overview of side effects caused by typical antipsychotics. Journal of Clinical Psychiatry 2000, 61(Suppl 8):S5-S11. (discussion 12-13).
8. Diagnostic and Statistical Manual of Mental Disorders : DSM-III-R 1987, American Psychiatric Association, Washington, DC. 3rd ed.
9. Baloush-Kleinman V., Levine S.Z., Roe D., Shnitt D., Weizman A., Poyurovsky M. Adherence to antipsychotic drug treatment in early-episode schizophrenia: a six-month naturalistic follow-up study. Schizophrenia Research 2011, 130:176-181.
10. Barkhof E., Meijer C.J., de Sonneville L.M.J., Linszen D.H., de Haan L. Interventions to improve adherence to antipsychotic medication in patients with schizophrenia-a review of the past decade. European Psychiatry 2012, 27:9-18.
11. Barnes T.R. A rating scale for drug-induced akathisia. British Journal of Psychiatry 1989, 154:672-676.
12. Barnes T.R.E., Shingleton-Smith A., Paton C. Antipsychotic long-acting injections: prescribing practice in the UK. British Journal of Psychiatry 2009, 195:S37-S42.
13. Baumann P., Hiemke C., Ulrich S., Eckermann G., Gaertner I., Gerlach M., Kuss H.J., Laux G., Müller-Oerlinghausen B., Rao M.L., Riederer P., Zernig G. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004, 37:243-265. Arbeitsge-meinschaft fur neuropsychopharmakologie und pharmakopsychiatrie.
14. Beck E.M., Cavelti M., Kvrgic S., Kleim B., Vauth R. Are we addressing the 'right stuff' to enhance adherence in schizophrenia? Understanding the role of insight and attitudes towards medication. Schizophrenia Research 2011, 132:42-49.
15. Becker M., Diamond R., Sainfort F. A new patient focused index for measuring quality of life in persons with severe and persistent mental illness. Quality of Life Research 1993, 2:239-251.
16. Bhanji N.H., Chouinard G., Margolese H.C. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. European Neuropsychopharmacology 2004, 14:87-92.
17. Birchwood M., Smith J., Drury V., Healy J., Macmillan F., Slade M. A self-report insight scale for psychosis: reliability, validity and sensitivity to change. Acta Psychiatrica Scandinavica 1994, 89:62-67.
18. Buchanan A. A two-year prospective study of treatment compliance in patients with schizophrenia. Psychological Medicine 1992, 22:787-797.
19. Budd R.J., Hughes I.C.T., Smith J.A. Health beliefs and compliance with antipsychotic medication. British Journal of Clinical Psychology 1996, 35:393-397.
20. Byerly M., Fisher R., Whatley K., Holland R., Varghese F., Carmody T., Magouirk B., Rush A.J. A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia. Psychiatry Research 2005, 133:129-133.
21. Byerly M.J., Nakonezny P.A., Rush A.J. The brief adherence rating scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder. Schizophrenia Research 2008, 100:60-69.
22. Cannon-Spoor H.E., Potkin S.G., Wyatt R.J. Measurement of premorbid adjustment in chronic schizophrenia. Schizophrenia Bulletin 1982, 8:470-484.
23. Caseiro O., Pérez-Iglesias R., Mata I., Martínez-Garcia O., Pelayo-Terán J.M., Tabares-Seisdedos R., Ortiz-García de la Foz V., Vázquez-Barquero J.L., Crespo-Facorro B. Predicting relapse after a first episode of non-affective psychosis: a three-year follow-up study. Journal of Psychiatric Research 2012, 46:1099-1105.
24. Chakos M., Lieberman J., Hoffman E., Bradford D., Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. The American Journal of Psychiatry 2001, 158:518-526.
25. Chisholm D., Knapp M.R., Knudsen H.C., Amaddeo F., Gaite L., van Wijngaarden B. Client socio-demographic and service receipt inventory-European version: development of an instrument for international research. Epsilon study 5. European psychiatric services: inputs linked to outcome domains and needs. British Journal of Psychiatry 2000, 177:S28-S33.
26. Chouinard G., Margolese H.C. Manual for the extrapyramidal symptom rating scale (ESRS). Schizophrenia Research 2005, 76:247-265.
27. Coldham E.L., Addington J., Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatrica Scandinavica 2002, 106:286-290.
28. David A.S. Insight and psychosis. British Journal of Psychiatry 1990, 156:798-808.
29. Day J.C., Wood G., Dewey M., Bentall R.P. A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients. British Journal of Psychiatry 1995, 166:650-653.
30. Day J.C., Bentall R.P., Roberts C., Randall F., Rogers A., Cattell D., Healy D., Rae P., Power C. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals. Archives of General Psychiatry 2005, 62:717-724.
31. De Hert M., Detraux J., van Winkel R., Yu W., Correll C.U. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nature Reviews Endocrinology 2012, 8:114-126.
32. Delis D.C. Integrating clinical assessment with cognitive neuroscience: construct validation of the california verbal learning test. Journal of Consulting and Clinical Psychology 1988, 56:123-130.
33. Delis D.C., Kramer J.H. Reliability and validity of the delis-kaplan executive function system: an update. Journal of the International Neuropsychological Society 2004, 10:301-303.
34. Diaz E., Neuse E., Sullivan M.C., Pearsall H.R., Woods S.W. Adherence to conventional and atypical antipsychotics after hospital discharge. Journal of Clinical Psychiatry 2004, 65:354-360.
35. Eker D., Arkar H. Perceived social support: psychometric properties of the MSPSS in normal and pathological groups in a developing country. Social Psychiatry Psychiatric Epidemiology 1995, 30:121-126.
36. Elliott R.A., Barber N., Horne R. Cost-effectiveness of adherence-enhancing interventions: A quality assessment of the evidence. Annals of Pharmacotherapy 2005, 39:508-515.
37. Elvevag B., Goldberg T.E. Cognitive impairment in schizophrenia is the core of the disorder. Critical Review in Neurobiology 2000, 14:1-21.
38. Faul F., Erdfelder E., Lang A.-G., Buchner A. G*power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behavior Research Methods 2007, 39:175-191.
39. Feldmann R., Buchkremer G., Minneker-Hügel E., Hornung W.P. Fragebogen zur erfassung der familienatmosphäre (fef): Einschätzung des emotionalen angehörigenverhaltens aus der sicht schizophrener patienten. Diagnostica 1995, 41:334-348.
40. Fenton W.S., Blyler C.R., Heinssen R.K. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophrenia Bulletin 1997, 23:637-651.
41. First M.B., Spitzer R.L., Gibbon M., Williams J.B. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Patient Edition. (SCID-I/P) Biometrics Research 1998, New York State Psychiatric Institute, New York.
42. Fleischhacker W.W., Oehl M.A., Hummer M. Factors influencing compliance in schizophrenia patients. Journal of Clinical Psychiatry 2003, 64(Suppl 16):S10-S13.
43. Franke G.H., Derogatis L.R. SCL-90-R: Die Symptom-Checkliste Von Derogatis: Deutsche Version 1995, Beltz Göttingen, Germany.
44. Garber M.C., Nau D.P., Erickson S.R., Aikens J.E., Lawrence J.B. The concordance of self-report with other measures of medication adherence: a summary of the literature. Medical Care 2004, 42:649-652.
45. Gray R., Leese M., Bindman J., Becker T., Burti L., David A., Gournay K., Kikkert M., Koeter M., Puschner B., Schene A., Thornicroft G., Tansella M. Adherence therapy for people with schizophrenia. British Journal of Psychiatry 2006, 189:508-514.
46. Guy W. ECDEU Assessment Manual for Psychopharmacology 1976, U. S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs, Rockville, Md.
47. Haro J.M., Kamath S.A., Ochoa S., Novick D., Rele K., Fargas A., Rodríguez M.J., Rele R., Orta J., Kharbeng A., Araya S., Gervin M., Alonso J., Mavreas V., Lavrentzou E., Liontos N., Gregor K., Jones P.B. The clinical global impression-schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatrica Scandinavica 2003, 107:16-23. SOHO Study Group.
48. Harrison G., Hopper K., Craig T., Laska E., Siegel C., Wanderling J., Dube K.C., Ganev K., Giel R., an der Heiden W., Holmberg S.K., Janca A., Lee P.W., Leon C.A., Malhotra S., Marsella A.J., Nakane Y., Sartorius N., Shen Y., Skoda C., Thara R., Tsirkin S.J., Varma V.K., Walsh D., Wiersma D. Recovery from psychotic illness: a 15- and 25-year international follow-up study. British Journal of Psychiatry 2001, 178:506-517.
49. Heinrichs D.W., Hanlon T.E., Carpenter W.T. The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin 1984, 10:388-398.
50. Higgins J.P.T., Altman D.G., Gøtzsche P.C., Jüni P., Moher D., Oxman A.D., Savović J., Schulz K.F., Weeks L., Sterne J.A.C. The cochrane collaboration's tool for assessing risk of bias in randomised trials. British Medical Journal 2011, 343. d5928.
51. Hogan T.P., Awad A.G., Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychological Medicine 1983, 13:177-183.
52. Hollingshead A.D.B., Redlich F.C. Social Class and Mental Illness: A Community Study 1958, Wiley, New York.
53. Horne R., Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. Journal of Psychosomatic Research 1999, 47:555-567.
54. Huang W.F., Cheng J.S., Lai I.C., Hsieh C.F. Medication compliance in outpatients with schizophrenia in one veterans hospital in taiwan. Journal of Food and Drug Analysis 2009, 17:401-407.
55. Jones P.B., Barnes T.R., Davies L., Dunn G., Lloyd H., Hayhurst K.P., Murray R.M., Markwick A., Lewis S.W. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (cutlass 1). Archives of General Psychiatry 2006, 63:1079-1087.
56. Jonsdottir H., Opjordsmoen S., Birkenaes A.B., Simonsen C., Engh J.A., Ringen P.A., Vaskinn A., Friis S., Sundet K., Andreassen O.A. Predictors of medication adherence in patients with schizophrenia and bipolar disorder. Acta Psychiatrica Scandinavica 2013, 127:23-33.
57. Julius R.J., Novitsky M.A.J., Dubin W.R. Medication adherence: a review of the literature and implications for clinical practice. Journal of Psychiatric Practice 2009, 15:34-44.
58. Jung H.Y., Joo Y.H., Shin H.K., Chung E.K., Kang U.G., Roh M.S., Kim Y.S. A validation study of korean-version of liverpool university neuroleptic side effect rating scale (LUNSERS). Journal of the Korean Neuropsychiatric Association 2002, 41:138-145.
59. Junghan U.M., Leese M., Priebe S., Slade M. Staff and patient perspectives on unmet need and therapeutic alliance in community mental health services. British Journal of Psychiatry 2007, 191:543-547.
60. Kahn R.S., Fleischhacker W.W., Boter H., Davidson M., Vergouwe Y., Keet I.P., Gheorghe M.D., Rybakowski J.K., Galderisi S., Libiger J., Hummer M., Dollfus S., Lopez-Ibor J.J., Hranov L.G., Gaebel W., Peuskens J., Lindefors N., Riecher-Rossler A., Grobbee D.E., group E.S. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. The Lancet 2008, 371:1085-1097.
61. Kamali M., Kelly B.D., Clarke M., Browne S., Gervin M., Kinsella A., Lane A., Larkin C., O'Callaghan E. A prospective evaluation of adherence to medication in first episode schizophrenia. European Psychiatry 2006, 21:29-33.
62. Karow A., Czekalla J., Dittmann R.W., Schacht A., Wagner T., Lambert M., Schimmelmann B.G., Naber D. Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia. Journal of Clinical Psychiatry 2007, 68:75-80.
63. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987, 13:261-276.
64. Keefe R.S., Mohs R.C., Bilder R.M., Harvey P.D., Green M.F., Meltzer H.Y., Gold J.M., Sano M. Neurocognitive assessment in the clinical antipsychotic trials of intervention effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale. Schizophrenia Bulletin 2003, 29:45-55.
65. Keefe R.S.E., Fenton W.S. How should DSM-V criteria for schizophrenia include cognitive impairment?. Schizophrenia Bulletin 2007, 33:912-920.
66. Kelly G.R., Mamon J.A., Scott J.E. Utility of the health belief model in examining medication compliance among psychiatric outpatients. Social Science and Medicine 1987, 25:1205-1211.
67. Kemp R., David A. Psychological predictors of insight and compliance in psychotic patients. British Journal of Psychiatry 1996, 169:444-450.
68. Kemp R., David A. Psychological predictors of insight and compliance in psychotic patients. British Journal of Psychiatry 1996, 169:444-450.
69. Kessler T.A. The cognitive appraisal of health scale: development and psychometric evaluation. Research in Nursing and Health 1998, 21:73-82.
70. Kikkert M.J., Barbui C., Koeter M.W., David A.S., Leese M., Tansella M., Gieler A., Puschner B., Schene A.H. Assessment of medication adherence in patients with schizophrenia: the achilles heel of adherence research. Journal of Nervous and Mental Disorders 2008, 196:274-281.
71. Kikkert M.J., Koeter M.W.J., Dekker J.J.M., Burti L., Robson D., Puschner B., Schene A.H. The predictive validity of subjective adherence measures in patients with schizophrenia. International Journal of Methods in Psychiatric Research 2011, 20:73-81.
72. Kim B., Lee S.H., Yang Y.K., Park J.I., Chung Y.C. Long-acting injectable antipsychotics for first-episode schizophrenia: the pros and cons. Schizophrenia Research and Treatment 2012, 2012:8. (Article ID 560836). 10.1155/2012/560836.
73. Kim J.H., Yim S.J., Yoon H.J. Assessing the reliability and validity of the korean version of the revised insight scale for psychosis (KISP). Schizophrenia Clinics 2004, 7:15-21.
74. Klingberg S., Schneider S., Wittorf A., Buchkremer G., Wiedemann G. Collaboration in outpatient antipsychotic drug treatment: analysis of potentially influencing factors. Psychiatry Research 2008, 161:225-234.
75. Lacro J.P., Dunn L.B., Dolder C.R., Leckband S.G., Jeste D.V. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. Journal of Clinical Psychiatry 2002, 63:892-909.
76. Lanouette N.M., Folsom D.P., Sciolla A., Jeste D.V. Psychotropic medication nonadherence among united states latinos: a comprehensive literature review. Psychiatr Services 2009, 60:157-174.
77. Lehman A.F. A quality of life interview for the chronically mentally ill. Evaluation and Program Planning 1988, 11:51-62.
78. Lepage M., Bodnar M., Joober R., Malla A. Is there an association between neurocognitive performance and medication adherence in first episode psychosis?. Early Intervention in Psychiatry 2010, 4:189-195.
79. Leucht S., Corves C., Arbter D., Engel R.R., Li C., Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. The Lancet 2009, 373:31-41.
80. Lieberman J.A., Phillips M., Gu H., Stroup S., Zhang P., Kong L., Ji Z., Koch G., Hamer R.M. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 2003, 28:995-1003.
81. Lieberman J.A., Tollefson G., Tohen M., Green A.I., Gur R.E., Kahn R.S., McEvoy J., Perkins D., Sharma T., Zipursky R., Wei H., Hamer R.M. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. American Journal of Psychiatry 2003, 160(8):1396-1404.
82. Lincoln T.M., Lüllmann E., Rief W. Correlates and long-term consequences of poor insight in patients with schizophrenia. A systematic review. Schizophrenia Bulletin 2007, 33:1324-1342.
83. Linden M., Nather J., Wilms H.U. Zur definition, bedeutung und messung der krankheitskonzepte von patienten: Die krankheitskonzeptskala (kk-skala) für schizophrene patienten. Fortschritte der Neurologie-Psychiatrie 1988, 56:35-43.
84. Lingjærde O., Ahlfors U.G., Bech P., Dencker S.J., Elgen K. The uku side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica 1987, 76:1-100.
85. Magaña A.B., Goldstein M.J., Karno M., Miklowitz D.J., Jenkins J., Falloon I.R.H. A brief method for assessing expressed emotion in relatives of psychiatric patients. Psychiatry Research 1986, 17:203-212.
86. Malla A., Norman R., Schmitz N., Manchanda R., Bechard-Evans L., Takhar J., Haricharan R. Predictors of rate and time to remission in first-episode psychosis: a two-year outcome study. Psychological Medicine 2006, 36:649-658.
87. Marder S.R. Overview of partial compliance. Journal of Clinical Psychiatry 2003, 64(Suppl 16):S3-S9.
88. Masand P.S., Roca M., Turner M.S., Kane J.M. Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review. Primary Care Companion to the Journal of Clinical Psychiatry 2009, 11:147-154.
89. McCabe R., Bullenkamp J., Hansson L., Lauber C., Martinez-Leal R., Rossler W., Salize H.J., Svensson B., Torres-Gonzalez F., van den Brink R., Wiersma D., Priebe S. The therapeutic relationship and adherence to antipsychotic medication in schizophrenia. PLoS One 2012, 7:e36080.
90. McEvoy J.P., Apperson L.J., Appelbaum P.S., Ortlip P., Brecosky J., Hammill K., Geller J.L., Roth L. Insight in schizophrenia. Its relationship to acute psychopathology. Journal of Nervous and Mental Disorders 1989, 177:43-47.
91. McEvoy J.P., Lieberman J.A., Stroup T.S., Davis S.M., Meltzer H.Y., Rosenheck R.A., Swartz M.S., Perkins D.O., Keefe R.S., Davis C.E., Severe J., Hsiao J.K. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. The American Journal of Psychiatry 2006, 163:600-610.
92. McIntosh A.M., Conlon L., Lawrie S.M., Stanfield A.C. Compliance therapy for schizophrenia. Cochrane Database of Systematic Reviews 2006, 3:CD003442.
93. Meier J., Becker T., Patel A., Robson D., Schene A., Kikkert M., Barbui C., Burti L., Puschner B. Effect of medication-related factors on adherence in people with schizophrenia: a european multi-centre study. Epidemiologia e Psichiatria Sociale 2010, 19:251-259.
94. Meier J., Becker T., Patel A., Robson D., Schene A., Kikkert M., Barbui C., Burti L., Puschner B. Effect of medication-related factors on adherence in people with schizophrenia: a european multi-centre study. Epidemiologia e Psichiatria Sociale 2010, 19:251-259.
95. Miller R., Ream G., McCormack J., Gunduz-Bruce H., Sevy S., Robinson D. A prospective study of cannabis use as a risk factor for non-adherence and treatment dropout in first-episode schizophrenia. Schizophrenia Research 2009, 113:138-144.
96. Misdrahi D., Petit M., Blanc O., Bayle F., Llorca P.M. The influence of therapeutic alliance and insight on medication adherence in schizophrenia. Nordic Journal of Psychiatry 2012, 66:49-54.
97. Mohamed S., Rosenheck R., McEvoy J., Swartz M., Stroup S., Lieberman J.A. Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. Schizophrenia Bulletin 2009, 35:336-346.
98. Morisky D.E., Green L.W., Levine D.M. Concurrent and predictive validity of a self-reported measure of medication adherence. Medical Care 1986, 24:67-74.
99. Morken G., Grawe R.W., Widen J.H. Effects of integrated treatment on antipsychotic medication adherence in a randomized trial in recent-onset schizophrenia. Jounal of Clinical Psychiatry 2007, 68:566-571.
100. Morken G., Widen J., Grawe R. Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry 2008, 8:32.
101. Mullins C.D., Obeidat N.A., Cuffel B.J., Naradzay J., Loebel A.D. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia. Schizophrenia Research 2008, 98:8-15.
102. Mutsatsa S.H., Joyce E.M., Hutton S.B., Webb E., Gibbins H., Paul S., Barnes T.R.E. Clinical correlates of early medication adherence: West London first episode schizophrenia study. Acta Psychiatrica Scandinavica 2003, 108:439-446.
103. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. International Clinical Psychopharmacology 1995, 10(Suppl 3):S133-S138.
104. Naber D., Moritz S., Lambert M., Rajonk F., Holzbach R., Mass R., Andresen B., Frank P., Rüdiger H., Reinhard M., Burghard A. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophrenia Research 2001, 50:79-88.
105. Norman R.M., Malla A.K., Verdi M.B., Hassall L.D., Fazekas C. Understanding delay in treatment for first-episode psychosis. Psychological Medicine 2004, 34:255-266.
106. Nosé M., Barbui C., Tansella M. How often do patients with psychosis fail to adhere to treatment programmes? A systematic review. Psychological Medicine 2003, 33:1149-1160.
107. Novick D., Haro J.M., Suarez D., Perez V., Dittmann R.W., Haddad P.M. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Research 2010, 176:109-113.
108. Oliver J.P.J., Huxley P.J., Priebe S., Kaiser W. Measuring the quality of life of severely mentally ill people using the lancashire quality of life profile. Socials Psychiatry and Psychiatric Epidemiology 1997, 32:76-83.
109. Osterberg L., Blaschke T. Adherence to medication. New England Journal of Medicine 2005, 353:487-497.
110. Perkins D.O., Johnson J.L., Hamer R.M., Zipursky R.B., Keefe R.S., Centorrhino F., Green A.I., Glick I.B., Kahn R.S., Sharma T., Tohen M., McEvoy J.P., Weiden P.J., Lieberman J.A. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophrenia Research 2006, 83:53-63.
111. Perkins D.O., Gu H., Weiden P.J., McEvoy J.P., Hamer R.M., Lieberman J.A. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. Journal of Clinical Psychiatry 2008, 69:106-113. Comparison of Atypicals in First Episode study.
112. Pinikahana J., Happell B., Taylor M., Keks N.A. Exploring the complexity of compliance in schizophrenia Issues in mental health nursing. Issues in Mental Health Nursing 2002, 23:513-528.
113. Pomykacz B., Mao M., Weiss R.D., Teter C.J. A review of brief medication-adherence instruments used in patients with schizophrenia and bipolar disorder. Harvard Review of Psychiatry 2007, 15:259-263.
114. Priebe S., Gruyters T. The role of the helping alliance in psychiatric community care. A prospective study. Journal of Nervous and Mental Disorders 1993, 181:552-557.
115. Quach P.L., Mors O., Christensen T.Ø., Krarup G., Jørgensen P., Bertelsen M., Jeppesen P., Petersen L., Thorup A., Nordentoft M. Predictors of poor adherence to medication among patients with first-episode schizophrenia-spectrum disorder. Early Intervention in Psychiatry 2009, 3:66-74.
116. Rabinovitch M., Bechard-Evans L., Schmitz N., Joober R., Malla A. Early predictors of nonadherence to antipsychotic therapy in first-episode psychosis. Canadian Journal of Psychiatry 2009, 54:28-35.
117. Remington G., Kwon J., Collins A., Laporte D., Mann S., Christensen B. The use of electronic monitoring (MEMS®) to evaluate antipsychotic compliance in outpatients with schizophrenia. Schizophrenia Research 2007, 90:229-237.
118. Reynolds G.P., Kirk S.L. Metabolic side effects of antipsychotic drug treatment-pharmacological mechanisms. Pharmacology and Therapeutics 2010, 125:169-179.
119. Roberts D.L., Velligan D.I. Medication adherence in schizophrenia. Drug Discovery Today: Therapeutic Strategies 2011, 8:11-15.
120. Robinson D.G., Woerner M.G., Alvir J.M.J., Bilder R.M., Hinrichsen G.A., Lieberman J.A. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophrenia Research 2002, 57:209-219.
121. Rush A., Gullion C., Basco M., Jarrett R., Trivedi M. The inventory of depressive symptomatology (IDS): psychometric properties. Psychological Medicine 1996, 26:477-486.
122. Sajatovic M., Velligan D.I., Weiden P.J., Valenstein M.A., Ogedegbe G. Measurement of psychiatric treatment adherence. Journal of Psychosomatic Research 2010, 69:591-599.
123. Schulz K.F., Altman D.G., Moher D. Consort 2010 statement: updated guidelines for reporting parallel group randomized trials. Annals of Internal Medicine 2010, 152:726-732.
124. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica 1970, Supplement 212:S11-S19.
125. Smith J., Birchwood M., Haddrell A. Informing people with schizophrenia about their illness: the effect of residual symptoms. Journal of Mental Health 1992, 1:61-70.
126. Spitzer R.L., Endicott J. Schedule for Affective Disorders and Schizophrenia-Change Version 1978, New York State Psychiatric Institute, New York. 3rd ed.
127. Subotnik K.L., Nuechterlein K.H., Ventura J., Gitlin M.J., Marder S., Mintz J., Hellemann G.S., Thornton L.A., Singh I.R. Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia. American Journal of Psychiatry 2011, 168:286-292.
128. Tait L., Birchwood M., Trower P. A new scale (SES) to measure engagement with community mental health services. Journal of Mental Health 2002, 11:191-198.
129. Tranulis C., Goff D., Henderson D.C., Freudenreich O. Becoming adherent to antipsychotics: A qualitative study of treatment-experienced schizophrenia patients. Psychiatric Services 2011, 62:888-892.
130. Velligan D., Sajatovic M., Valenstein M., Riley W.T., Safren S., Lewis-Fernandez R., Weiden P., Ogedegbe G., Jamison J. Methodological challenges in psychiatric treatment adherence research. Clinical Schizophrenia and Related Psychoses 2010, 4:74-91.
131. Velligan D.I., Lam Y.W., Glahn D.C., Barrett J.A., Maples N.J., Ereshefsky L., Miller A.L. Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophrenia Bulletin 2006, 32:724-742.
132. Velligan D.I., Wang M., Diamond P., Glahn D.C., Castillo D., Bendle S., Lam Y.W., Ereshefsky L., Miller A.L. Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatric Services 2007, 58:1187-1192.
133. Velligan D.I., Weiden P.J., Sajatovic M., Scott J., Carpenter D., Ross R., Docherty J.P. Assessment of adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines. Journal of Psychiatric Practice 2010, 16:34-45.
134. Velligan D.I., Weiden P.J., Sajatovic M., Scott J., Carpenter D., Ross R., Docherty J.P. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. Journal of Clinical Psychiatry 2009, 70(Suppl 4):S1-S46. Expert Consensus Panel on Adherence Problems in Serious and Persistent Mental Illness.
135. Ventura J., Green M.F., Shaner A., Liberman R.P. Training and quality assurance with the brief psychiatric rating scale: "The drift busters". International Journal of Methods in Psychiatric Research 1993, 3:221-244.
136. von Elm E., Altman D.G., Egger M., Pocock S.J., Gøtzsche P.C., Vandenbroucke J.P. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Bulletin of the World Health Organization 2007, 85:867-872. STROBE Initiative.
137. Voruganti L.P., Baker L.K., Awad A.G. New generation antipsychotic drugs and compliance behaviour. Current Opinion in Psychiatry 2008, 21:133-139.
138. Wechsler D. Wechsler Adult Intelligence Scale-III 1997, The Psychological Corporation, San Antonio (TX), USA.
139. Wechsler D. Wechsler Memory Scale 1997, The Psychological Corporation, San Antonia, TX, USA. third ed.
140. Weiden P.J. Understanding and addressing adherence issues in schizophrenia: From theory to practice. Journal of Clinical Psychiatry 2007, 68(Suppl 14):14-19.
141. Weiden P., Zygmunt A. The road back: working with the severely mentally ill. Medication noncompliance in schizophrenia: I. Assessment. Journal of Practical Psychiatry and Behavioral Health 1997, 3:106-110.
142. West S., King V., Carey T.S., Lohr K.N., McKoy N., Sutton S.F., Lux L. Systems to Rate the Strength of Scientific Evidence 2002, 1-11. (Evidence Report/Technology Assessment (Summary).
143. Yang J., Ko Y.H., Paik J.W., Lee M.S., Han C., Joe S.H., Jung I.K., Jung H.G., Kim S.H. Symptom severity and attitudes toward medication: impacts on adherence in outpatients with schizophrenia. Schizophrenia Research 2012, 134:226-231.
144. Young R.C., Biggs J.T., Ziegler V.E., Meyer D.A. A rating scale for mania: reliability, validity and sensitivity. British Journal of Psychiatry 1978, 133:429-435.
145. Zygmunt A., Olfson M., Boyer C.A., Mechanic D. Interventions to improve medication adherence in schizophrenia. American Journal of Psychiatry 2002, 159:1653-1664.